Alphageneron Pharmaceuticals
Blood & Organ Banks · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1441 Broadway Fl 3 Ste 3159, New York, N...Phone Number
(646) 569-5522Website
www.alphageneron.comRevenue
<$5 MillionIndustry
ZI Rank: 3
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
2
2
2
1
3
About Alphageneron Pharmaceuticals
Alphageneron Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing targeted natural killer (NK) cell therapies for cancer treatment, supported by Companion Diagnostics. Their product lineup includes autologous and allogeneic NK cell therapies, such as ENKASTIM and AP-161, which specifically target tumors expressing the membrane Hsp70 biomarker. The company aims to transform the lives of cancer patients through innovative therapies and is staffed by industry veterans with extensive experience in pharmaceuticals and biotechnology. Based in Boston, Massachusetts, Alphageneron also has capabilities in Munich, Germany.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alphageneron Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Alphageneron Pharmaceuticals had a recent Job posting/layoffs
Check out if Alphageneron Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Alphageneron Pharmaceuticals
Funding: Get notified immidiatlly once Alphageneron Pharmaceuticals has new funding data
Check if Alphageneron Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Alphageneron Pharmaceuticals launches new products
Alphageneron Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Alphageneron Pharmaceuticals recently announced quarterly report
Recommended Actions
Find VP level buyers at Alphageneron Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Alphageneron Pharmaceuticals
Compare insights from companies similar to Alphageneron Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Alphageneron Pharmaceutic...
<$5M
1-10
Private
-
2020
N/A
Company Profile Activity
Activity Insights
Alphageneron Pharmaceuticals is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Alphageneron Pharmaceuticals is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Alphageneron Pharmaceuticals.
Alphageneron Pharmaceuticals Tech Stack
A closer look at the technologies used by Alphageneron Pharmaceuticals
See more technologies
Alphageneron Pharmaceuticals News & Media
Alphageneron Announces Successful Completion of FDA Pre-IND Meeting of Proposed Phase II Clinical Trial for NK Cell Therapy with Advanced (stage III & Stage IV) NSCLC Patients
CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a clinical stage pharmaceutical company with a robust product portfolio of autologous and allogeneic natural killer (“NK”) cell, allogeneic CAR NK cell and antibody-based therapies targeting highly resistant tumors and viral infections, announces the successful completion of a pre-IND (“Investigational New Drug”) meeting with the U.S. Food and Drug Administration (“FDA”) regaAlphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021
CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alphageneron Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Alphageneron Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing targeted natural killer (NK) cell therapies for cancer treatment, supported by Companion Diagnostics. Their product lineup includes autologous and allogeneic NK cell therapies, such as ENKASTIM and AP-161, which specifically target tumors expressing t... Read More
